Reading the tree leaves-how to enrich clinical trials of diabetic kidney disease.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 28646994.
- Also identified by DOI 10.1016/j.kint.2017.03.042 and PMC identifier 6380356.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Most participants selected for clinical trials of renoprotective drugs do not reach approved endpoints; thus, large trials or prolonged follow-up are needed to achieve adequate statistical power. Yamanouchi et al. used a classification and regression trees analysis to enrich enrollment criterion for patients at the highest risk of reaching these outcomes. Their findings suggest a greater role for newly identified biomarkers of diabetic kidney disease in the selection of participants for clinical trials.
Medical subject headings
- Diabetic Nephropathies
- Reading